CD110 Polyclonal Antibody

In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs. TPO-R deficient mice were severely thrombocytopenic, emphasizing the important role of CD110 and thrombopoietin in megakaryocyte and platelet formation. Upon binding of thrombopoietin CD110 is dimerized and the JAK family of non-receptor tyrosine kinases, as well as the STAT family, the MAPK family, the adaptor protein Shc and the receptors themselves become tyrosine phosphorylated.

The CD110 Polyclonal Antibody is a highly specific and sensitive immunological tool designed for the detection and quantification of CD110 protein expression in various biological samples. This antibody is produced using advanced recombinant DNA technology, ensuring high purity and batch-to-batch consistency.

The CD110 Polyclonal Antibody exhibits exceptional affinity and specificity towards the CD110 protein, making it an ideal choice for a wide range of applications, including Western blotting, immunohistochemistry, and flow cytometry. It recognizes both the native and denatured forms of CD110, enabling reliable and accurate detection in various experimental conditions.

With its superior sensitivity, the CD110 Polyclonal Antibody allows for the detection of low levels of CD110 protein expression, making it suitable for both qualitative and quantitative analysis. Its robust performance ensures reliable and reproducible results, facilitating precise and meaningful data interpretation.

The CD110 Polyclonal Antibody is supplied in a convenient and ready-to-use format, eliminating the need for time-consuming and complex preparation steps. It is provided in a liquid formulation, allowing for easy handling and minimizing the risk of sample contamination.

This antibody has been extensively validated using a variety of cell lines and tissue samples, ensuring its reliability and accuracy. It exhibits minimal cross-reactivity with other proteins, further enhancing its specificity and reducing the likelihood of false-positive results.

In summary, the CD110 Polyclonal Antibody is a highly reliable and specific immunological tool for the detection and quantification of CD110 protein expression. Its exceptional sensitivity, robust performance, and convenient format make it an invaluable asset for researchers in the fields of immunology, oncology, and molecular biology.